{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
BLA125070
(2004)
Source URL:
First approved in 2004
Source:
BLA125070
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
First approved in 2002
Source:
BLA103666
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2021)
Source URL:
First approved in 2000
Source:
ANDA205622
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
M001
(1998)
Source URL:
First approved in 1998
Source:
M001
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
BLA103237
(1989)
Source URL:
First approved in 1989
Source:
BLA103237
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
ANDA088042
(1984)
Source URL:
First approved in 1984
Source:
ANDA088042
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
ANDA076258
(1968)
Source URL:
First approved in 1968
Source:
ANDA076258
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
NCT03180034: Phase 4 Interventional Enrolling by invitation Human Papillomavirus Infection
(2017)
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
NCT03180034: Phase 4 Interventional Enrolling by invitation Human Papillomavirus Infection
(2017)
Source URL:
Class:
CONCEPT